Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Latest: SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates (Zacks Investment Research)
From news headlines · Not investment advice
Latest: SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates (Zacks Investment Research)
No confirmed cause yet: the newest headline naming the stock.
Last check 7:30 PM ET
Headlines open the publisher's site.Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about SOPH?
Zacks Investment Research
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue EstimatesSOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.
Headlines open the publisher's site.
No threads yet
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
